المؤلفون: Radich, Jerald P., Hochhaus, Andreas, Masszi, Tamás, Hellmann, Andrzej, Stentoft, Jesper, Casares, María Teresa Gómez, García-Gutiérrez, J. Valentín, Conneally, Eibhlin, le Coutre, Philipp D., Gattermann, Norbert, Martino, Bruno, Saussele, Susanne, Giles, Francis J., Ross, David M., Aimone, Paola, Li, Sai, Titorenko, Ksenia, Saglio, Giuseppe

المصدر: Radich , J P , Hochhaus , A , Masszi , T , Hellmann , A , Stentoft , J , Casares , M T G , García-Gutiérrez , J V , Conneally , E , le Coutre , P D , Gattermann , N , Martino , B , Saussele , S , Giles , F J , Ross , D M , Aimone , P , Li , S , Titorenko , K & Saglio , G 2021 , ' Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia : 5-year update of ....

مصطلحات موضوعية: KINASE INHIBITOR THERAPY, SURVIVAL, MAJOR MOLECULAR RESPONSE, CML, MANAGEMENT, IMATINIB, DASATINIB, DISCONTINUATION, CESSATION, Humans, Kaplan-Meier Estimate, Male, Survival Rate, Treatment Outcome, Leukemia, Myeloid, Chronic-Phase/drug therapy, Pyrimidines/therapeutic use, Myelogenous, Chronic, BCR-ABL Positive/drug therapy, Adolescent, Protein Kinase Inhibitors/therapeutic use, Female

وصف الملف: application/pdf

الإتاحة: https://doi.org/10.1038/s41375-021-01205-5Test
https://pure.au.dk/portal/da/publications/treatmentfree-remission-following-frontline-nilotinib-in-patients-with-chronic-phase-chronic-myeloid-leukemiaTest(8a362493-6e7f-4345-a1da-c05d5478eeb8).html
https://pure.au.dk/ws/files/273705470/s41375_021_01205_5.pdfTest
http://www.scopus.com/inward/record.url?scp=85102338270&partnerID=8YFLogxKTest

المؤلفون: Brümmendorf, Tim H., Gambacorti-Passerini, Carlo, Bushmakin, Andrew G., Cappelleri, Joseph C., Viqueira, Andrea, Reisman, Arlene, Isfort, Susanne, Mamolo, Carla

المصدر: http://lobid.org/resources/99370678538206441Test#!, 99(6):1241-1249.

مصطلحات موضوعية: Aniline Compounds/therapeutic use [MeSH], Health-related quality of life, Nitriles/therapeutic use [MeSH], Quinolines/therapeutic use [MeSH], Molecular response, Humans [MeSH], Treatment Outcome [MeSH], Quality of Life/psychology [MeSH], Imatinib, Leukemia, Myeloid, Chronic-Phase/blood [MeSH], Chronic-Phase/psychology [MeSH], Original Article, Chronic-Phase/drug therapy [MeSH], Chronic myeloid leukemia, Antineoplastic Agents/therapeutic use [MeSH], Bosutinib, Imatinib Mesylate/therapeutic use [MeSH]

العلاقة: https://repository.publisso.de/resource/frl:6466980Test; https://doi.org/10.1007/s00277-020-04018-1Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237399Test/

الإتاحة: https://doi.org/10.1007/s00277-020-04018-1Test
https://repository.publisso.de/resource/frl:6466980Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237399Test/

المؤلفون: Jerald P. Radich, David M. Ross, Bruno Martino, Susanne Saussele, María Teresa Gómez Casares, Andreas Hochhaus, Eibhlin Conneally, Giuseppe Saglio, Philipp le Coutre, Norbert Gattermann, Tamás Masszi, Sai Li, Francis J. Giles, Jesper Stentoft, Andrzej Hellmann, Paola Aimone, Ksenia Titorenko, J. Valentín García-Gutiérrez

المصدر: Radich, J P, Hochhaus, A, Masszi, T, Hellmann, A, Stentoft, J, Casares, M T G, García-Gutiérrez, J V, Conneally, E, le Coutre, P D, Gattermann, N, Martino, B, Saussele, S, Giles, F J, Ross, D M, Aimone, P, Li, S, Titorenko, K & Saglio, G 2021, ' Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia : 5-year update of the ENESTfreedom trial ', Leukemia, vol. 35, no. 5, pp. 1344-1355 . https://doi.org/10.1038/s41375-021-01205-5Test
Leukemia

مصطلحات موضوعية: Male, Cancer Research, medicine.medical_specialty, Adolescent, Protein Kinase Inhibitors/therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy, DISCONTINUATION, Kaplan-Meier Estimate, IMATINIB, Article, Phase II trials, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Internal medicine, medicine, MANAGEMENT, Humans, In patient, Adverse effect, MAJOR MOLECULAR RESPONSE, Protein Kinase Inhibitors, Survival rate, CML, Chronic myeloid leukaemia, DASATINIB, Framingham Risk Score, business.industry, Leukemia, Myeloid, Chronic-Phase/drug therapy, Incidence (epidemiology), KINASE INHIBITOR THERAPY, Myeloid leukemia, Pyrimidines/therapeutic use, Hematology, Chronic phase chronic myeloid leukemia, Survival Rate, Pyrimidines, Treatment Outcome, Oncology, Nilotinib, Leukemia, Myeloid, Chronic-Phase, SURVIVAL, Female, CESSATION, business, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9b2998b5b263037b3d3f86c7e5684fcTest
https://pure.au.dk/portal/da/publications/treatmentfree-remission-following-frontline-nilotinib-in-patients-with-chronic-phase-chronic-myeloid-leukemiaTest(8a362493-6e7f-4345-a1da-c05d5478eeb8).html

المساهمون: Sang Kyun Sohn, Suk Joong Oh, Byung Soo Kim, Hun Mo Ryoo, Joo Seop Chung, Young Don Joo, Soo Mee Bang, Chul Won Jung, Dong Hwan Kim, Sung Soo Yoon, Ho In Kim, Hong Ghi Lee, Jong Ho Won, Yoo Hong Min, June Won Cheong, Joon Seong Park, Ki Seong Eom, Myung Soo Hyun, Min Kyoung Kim, Hawk Kim, Moo Rim Park, Jinny Park, Chul Soo Kim, Hyeoung Joon Kim, Yeo Kyeoung Kim, Eun Kyung Park, Dae Young Zang, Deog Yeon Jo, Joon Ho Moon, Seon Yang Park, Min, Yoo Hong, Cheong, June Won, Cheong, June-Won

مصطلحات موضوعية: Adolescent, Adult, Aged, Antineoplastic Agents/adverse effects, Antineoplastic Agents/pharmacokinetics, Antineoplastic Agents/therapeutic use, Benzamides, Female, Fusion Proteins, bcr-abl/genetics, Humans, Imatinib Mesylate, Leukemia, Myeloid, Chronic-Phase/drug therapy, Chronic-Phase/genetics, Logistic Models, Male, Neutropenia/chemically induced, Piperazines/blood, Piperazines/pharmacokinetics, Piperazines/therapeutic use, Prospective Studies, Pyrimidines/blood, Pyrimidines/pharmacokinetics, Pyrimidines/therapeutic use, Reverse Transcriptase Polymerase Chain Reaction, Thrombocytopenia/chemically induced, Time Factors, Transcription

وصف الملف: 1024~1029

العلاقة: LEUKEMIA & LYMPHOMA; J02165; OAK-2011-01235; https://ir.ymlib.yonsei.ac.kr/handle/22282913/93761Test; T201102938; LEUKEMIA & LYMPHOMA, Vol.52(6) : 1024-1029, 2011

الإتاحة: https://doi.org/10.3109/10428194.2011.563885Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/93761Test

المساهمون: Kyu-Hyun Yang, Si-Young Park, Sang-Won Park, Soon-Hyuck Lee, Seung-Beom Han, Woong-Kyo Jung, Suk-Jin Kim, Yang, Kyu Hyun

مصطلحات موضوعية: Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Benzamides, Bone Remodeling/drug effects, Bone and Bones/diagnostic imaging, Bone and Bones/drug effects, Bone and Bones/metabolism, Bone and Bones/pathology, Female, Femoral Fractures/blood, Femoral Fractures/diagnostic imaging, Femoral Fractures/etiology, Femoral Fractures/surgery, Humans, Hyperparathyroidism, Secondary/chemically induced, Secondary/physiopathology, Hypophosphatemia/chemically induced, Hypophosphatemia/physiopathology, Imatinib Mesylate, Leukemia, Myeloid, Chronic-Phase/drug therapy, Middle Aged, Piperazines/adverse effects, Piperazines/therapeutic use, Pyrimidines/adverse effects, Pyrimidines/therapeutic use, Radiography, Insufficient fracture

وصف الملف: 713~718

العلاقة: JOURNAL OF BONE AND MINERAL METABOLISM; J01277; OAK-2010-01928; https://ir.ymlib.yonsei.ac.kr/handle/22282913/102328Test; http://link.springer.com/article/10.1007%2Fs00774-010-0203-2Test; T201003517; JOURNAL OF BONE AND MINERAL METABOLISM, Vol.28(6) : 713-718, 2010

الإتاحة: https://doi.org/10.1007/s00774-010-0203-2Test
https://ir.ymlib.yonsei.ac.kr/handle/22282913/102328Test

المؤلفون: Ben Lakhal, Raihane, Ghedira, Hela, Bellaaj, Hatem, Ben Youssef, Yosra, Menif, Samia, Manai, Zeineb, Bedoui, Manel, Lakhal, Amel, M'Sadek, Fehmi, Elloumi, Moez, Khélif, Abderrahmane, Ben Romdhane, Neila, Laatiri, Mohamed Adnène, Ben Othmen, Tarek, Meddeb, Balkis

المساهمون: Hôpital Universitaire Aziza Othmana Tunis, Hôpital militaire de Tunis, Hedi Chaker Hospital Sfax, CHU Farhat Hached Sousse, Laboratoire d'hématologie moléculaire et cellulaire (LR11IPT07), Institut Pasteur de Tunis, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Hôpital La Rabta Tunis, CHU Fattouma Bourguiba Monastir (HFB), Centre National de Greffe de la Moëlle osseuse Tunis (CNGMO)

المصدر: ISSN: 0939-5555.

مصطلحات موضوعية: Tunisia, Survey, Imatinib, Clinical practice, CML, Management, MESH: Adolescent, MESH: Adult, MESH: Leukemia, Myeloid, Chronic-Phase/drug therapy, Chronic-Phase/epidemiology, MESH: Aged, Chronic-Phase/pathology, MESH: Male, MESH: Middle Aged, MESH: Practice Patterns, Physicians', MESH: Prognosis, MESH: Protein Kinase Inhibitors/adverse effects, MESH: Protein Kinase Inhibitors/therapeutic use, MESH: Humans, MESH: Retrospective Studies, MESH: Splenomegaly/etiology, MESH: Splenomegaly/pathology, 80 and over, MESH: Splenomegaly/prevention & control, MESH: Survival Analysis, MESH: Tumor Burden/drug effects, MESH: Tunisia/epidemiology

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/29305630; hal-01876259; https://hal.science/hal-01876259Test; PUBMED: 29305630

الإتاحة: https://doi.org/10.1007/s00277-017-3224-2Test
https://hal.science/hal-01876259Test

المؤلفون: Samia Menif, Amel Lakhal, Yosra Ben Youssef, Raihane Ben Lakhal, Manel Bedoui, Z. Manai, Mohamed Adnène Laatiri, Tarek Ben Othmen, Hela Ghedira, Neila Ben Romdhane, Abderrahmane Khélif, Hatem Bellaaj, F. Msadek, Balkis Meddeb, Moez Elloumi

المساهمون: Hôpital Universitaire Aziza Othmana [Tunis], Hôpital militaire de Tunis, Hedi Chaker Hospital [Sfax], CHU Farhat Hached [Sousse], Laboratoire d'hématologie moléculaire et cellulaire (LR11IPT07), Institut Pasteur de Tunis, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Hôpital La Rabta [Tunis], CHU Fattouma Bourguiba [Monastir] (HFB), Centre National de Greffe de la Moëlle osseuse Tunis (CNGMO)

المصدر: Annals of Hematology
Annals of Hematology, Springer Verlag, 2018, 97 (4), pp.597--604. ⟨10.1007/s00277-017-3224-2⟩

مصطلحات موضوعية: Male, MESH: Leukemia, Myeloid, Accelerated Phase/drug therapy, MESH: Splenomegaly/prevention & control, MESH: Tunisia/epidemiology, Clinical practice, Tyrosine-kinase inhibitor, 0302 clinical medicine, MESH: Leukemia, Myeloid, Chronic-Phase/drug therapy, MESH: Aged, 80 and over, MESH: Child, Epidemiology, Medicine, MESH: Imatinib Mesylate/therapeutic use, Practice Patterns, Physicians', Child, Survey, CML, Aged, 80 and over, MESH: Aged, Hematology, MESH: Middle Aged, Myeloid leukemia, General Medicine, MESH: Follow-Up Studies, Middle Aged, Prognosis, 3. Good health, Tumor Burden, Management, Leukemia, MESH: Young Adult, MESH: Imatinib Mesylate/adverse effects, 030220 oncology & carcinogenesis, Child, Preschool, MESH: Survival Analysis, Leukemia, Myeloid, Chronic-Phase, MESH: Leukemia, Myeloid, Chronic-Phase/epidemiology, Imatinib Mesylate, MESH: Leukemia, Myeloid, Accelerated Phase/pathology, Female, MESH: Antineoplastic Agents/therapeutic use, Sokal Score, medicine.drug, Adult, medicine.medical_specialty, Tunisia, Adolescent, medicine.drug_class, Antineoplastic Agents, Leukemia, Myeloid, Accelerated Phase, MESH: Prognosis, 03 medical and health sciences, Young Adult, Internal medicine, MESH: Leukemia, Myeloid, Chronic-Phase/diagnosis, Humans, MESH: Leukemia, Myeloid, Chronic-Phase/pathology, Adverse effect, Protein Kinase Inhibitors, Aged, Retrospective Studies, MESH: Adolescent, MESH: Humans, business.industry, MESH: Child, Preschool, Imatinib, MESH: Adult, MESH: Retrospective Studies, MESH: Protein Kinase Inhibitors/adverse effects, medicine.disease, Survival Analysis, MESH: Male, MESH: Protein Kinase Inhibitors/therapeutic use, MESH: Splenomegaly/pathology, MESH: Leukemia, Myeloid, Accelerated Phase/epidemiology, Splenomegaly, MESH: Practice Patterns, Physicians', MESH: Leukemia, Myeloid, Accelerated Phase/diagnosis, MESH: Splenomegaly/etiology, business, MESH: Tumor Burden/drug effects, MESH: Female, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, 030215 immunology, Follow-Up Studies, MESH: Antineoplastic Agents/adverse effects

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66925fcc39af00c0fb63c3b0c040da14Test
https://hal.archives-ouvertes.fr/hal-01876259Test